Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging
暂无分享,去创建一个
James R. Johnson | K. Devarajan | A. Godwin | M. von Mehren | D. Piwnica-Worms | L. Rink | H. Hensley
[1] M. von Mehren,et al. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. , 2013, Hematology/oncology clinics of North America.
[2] J. Sicklick,et al. In Vivo Fluorescence Imaging of Gastrointestinal Stromal Tumors Using Fluorophore-Conjugated Anti-KIT Antibody , 2013, Annals of Surgical Oncology.
[3] Ian Ingram. FDA approves regorafenib (Stivarga) for GIST. , 2013, Oncology.
[4] J. Fletcher,et al. A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[6] James R. Johnson,et al. Caspase-activated cell-penetrating peptides reveal temporal coupling between endosomal release and apoptosis in an RGC-5 cell model. , 2012, Bioconjugate chemistry.
[7] J. Fletcher,et al. p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors , 2012, PloS one.
[8] C. Nanni,et al. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET , 2010, Journal of experimental & clinical cancer research : CR.
[9] T. Seierstad,et al. Monitoring the Effect of Targeted Therapies in a Gastrointestinal Stromal Tumor Xenograft Using a Clinical PET/CT , 2010, Molecular Imaging and Biology.
[10] Bohumil Bednar,et al. Dual In Vivo Quantification of Integrin-targeted and Protease-activated Agents in Cancer Using Fluorescence Molecular Tomography (FMT) , 2010, Molecular Imaging and Biology.
[11] D. Fisher,et al. Role for the Proapoptotic Factor BIM in Mediating Imatinib-induced Apoptosis in a c-KIT-dependent Gastrointestinal Stromal Tumor Cell Line* , 2010, The Journal of Biological Chemistry.
[12] W. M. Leevy,et al. Optical imaging of mammary and prostate tumors in living animals using a synthetic near infrared zinc(II)-dipicolylamine probe for anionic cell surfaces. , 2010, Journal of the American Chemical Society.
[13] David Piwnica-Worms,et al. Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model , 2009, Proceedings of the National Academy of Sciences.
[14] David Piwnica-Worms,et al. An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. , 2009, Bioconjugate chemistry.
[15] C. Nanni,et al. Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model , 2009, Clinical and Experimental Medicine.
[16] J. Fletcher,et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway , 2007, Oncogene.
[17] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Desai,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[19] K. Araki,et al. STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response. , 2006, International journal of molecular medicine.
[20] J. Blay,et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.
[21] R. Herings,et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. , 2005, European journal of cancer.
[22] David M. Thomas,et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. , 2005, Cancer research.
[23] Bradley D. Smith,et al. New reagents for phosphatidylserine recognition and detection of apoptosis. , 2005, Bioorganic & medicinal chemistry.
[24] T. Shuin,et al. Conventional and Molecular Cytogenetic Characterization of a New Human Cell Line, GIST-T1, Established from Gastrointestinal Stromal Tumor , 2002, Laboratory Investigation.